| [1] |
Roth, G.A.; Johnson, C.; Abajobir, A.; Abd-Allah, F.; Abera, S.F.; Abyu, G.; Ahmed, M.; Aksut, B.; Alam, T.; Alam, K.; Alla, F.; Alvis-Guzman, N.; Amrock, S.; Ansari, H.; Ärnlöv, J.; Asayesh, H.; Atey, T.M.; Avila-Burgos, L.; Murray, C. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J. Am. Coll. Cardiol. 2017, 70, 1–25.
|
| [2] |
Members, W.G.; Mozaffarian, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; Das, S.R.; de Ferranti, S.; Després, J.P.; Fullerton, H.J.; Howard, V.J.; Huffman, M.D.; Isasi, C.R.; Jiménez, M.C.; Judd, S.E.; Kissela, B.M.; Lichtman, J.H.; Lisabeth, L.D.; Liu, S.M.; Mackey, R.H.; Magid, D.J.; McGuire, D.K.; Mohler, E.R.; Moy, C.S.; Muntner, P.; Mussolino, M.E.; Nasir, K.; Neumar, R.W.; Nichol, G.; Palaniappan, L.; Pandey, D.K.; Reeves, M.J.; Rodriguez, C.J.; Rosamond, W.; Sorlie, P.D.; Stein, J.; Towfighi, A.; Turan, T.; Virani, S.S.; Woo, D.; Yeh, R.W.; Turner, M.B.; Committee, A.H.A.S.; Subcommittee, S.S. Heart disease and stroke statistics-2016 update: a report from the American heart association. Circulation. 2016, 133, e38–e360.
|
| [3] |
McMurray, J.J.V.; Packer, M.; Desai, A.S.; Gong, J.; Lefkowitz, M.P.; Rizkala, A.R.; Rouleau, J.; Shi, V.C.; Solomon, S.D.; Swedberg, K.; Zile, M.R.; Investigators, P.H.C.A. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur. J. Heart Fail. 2013, 15, 1062–1073.
|
| [4] |
Jessup, M. Neprilysin inhibition: a novel therapy for heart failure. N. Engl. J. Med. 2014, 371, 1062–1064.
|
| [5] |
Yandrapalli, S.; Aronow, W.S.; Mondal, P.; Chabbott, D.R. The evolution of natriuretic peptide augmentation in management of heart failure and the role of sacubitril/valsartan. Arch. Med. Sci. 2017, 13, 1207–1216.
|
| [6] |
Jessup, M. Neprilysin inhibition: a novel therapy for heart failure. N. Engl. J. Med. 2014, 371, 1062–1064.
|
| [7] |
Lang, C.C.; Struthers, A.D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat. Rev. Cardiol. 2013, 10, 125–134.
|
| [8] |
Gori, M.; D'Elia, E.; Senni, M. Sacubitril/valsartan therapeutic strategy in HFpEF: clinical insights and perspectives. Int. J. Cardiol. 2019, 281, 158–165.
|
| [9] |
Owan, T.E.; Hodge, D.O.; Herges, R.M.; Jacobsen, S.J.; Roger, V.L.; Redfield, M.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N. Engl. J. Med. 2006, 355, 251–259.
|
| [10] |
Senni, M.; Paulus, W.J.; Gavazzi, A.; Fraser, A.G.; Díez, J.; Solomon, S.D.; Smiseth, O.A.; Guazzi, M.; Lam, C.S.P.; Maggioni, A.P.; Tschöpe, C.; Metra, M.; Hummel, S.L.; Edelmann, F.; Ambrosio, G.; Stewart Coats, A.J.; Filippatos, G.S.; Gheorghiade, M.; Anker, S.D.; Levy, D.; Pfeffer, M.A.; Stough, W.G.; Pieske, B.M. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur. Heart J. 2014, 35, 2797–2815.
|
| [11] |
D’Elia, E.; Vaduganathan, M.; Gori, M.; Gavazzi, A.; Butler, J.; Senni, M. Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur. J. Heart Fail. 2015, 17, 1231–1239.
|
| [12] |
Hamdani, N.; Bishu, K.G.; von Frieling-Salewsky, M.; Redfield, M.M.; Linke, W.A. Deranged myofilament phosphorylation and function in experimental heart failure with preserved ejection fraction. Cardiovasc. Res. 2012, 97, 464–471.
|
| [13] |
van Heerebeek, L.; Hamdani, N.; Falcão-Pires, I.; Leite-Moreira, A.F.; Begieneman, M.P.V.; Bronzwaer, J.G.F.; van der Velden, J.; Stienen, G.J.M.; Laarman, G.J.; Somsen, A.; Verheugt, F.W.A.; Niessen, H.W.M.; Paulus, W.J. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012, 126, 830–839.
|
| [14] |
Krüger, M.; Kötter, S.; Grützner, A.; Lang, P.; Andresen, C.; Redfield, M.M.; Butt, E.; dos Remedios, C.G.; Linke, W.A. Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs. Circ. Res. 2009, 104, 87–94.
|
| [15] |
Paulus, W.J.; Tschöpe, C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J. Am. Coll. Cardiol. 2013, 62, 263–271.
|
| [16] |
Franssen, C.; Chen, S.; Unger, A.; Korkmaz, H.I.; de Keulenaer, G.W.; Tschöpe, C.; Leite-Moreira, A.F.; Musters, R.; Niessen, H.W.M.; Linke, W.A.; Paulus, W.J.; Hamdani, N. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction. JACC Heart Fail. 2016, 4, 312–324.
|
| [17] |
Ahluwalia, A.; MacAllister, R.J.; Hobbs, A.J. Vascular actions of natriuretic peptides. Basic Res. Cardiol. 2004, 99, 83–89.
|
| [18] |
Shaw, R.M.; Nikolova, A.P. A surprising noncanonical role for calcineurin in pressure-induced cardiac hypertrophy. J. Am. Coll. Cardiol. 2018, 71, 668–669.
|
| [19] |
Gu, J.; Noe, A.; Chandra, P.; Al-Fayoumi, S.; Ligueros-Saylan, M.; Sarangapani, R.; Maahs, S.; Ksander, G.; Rigel, D.F.; Jeng, A.Y.; Lin, T.H.; Zheng, W.Y.; Dole, W.P. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor—neprilysin inhibitor (ARNi). J. Clin. Pharmacol. 2010, 50, 401–414.
|
| [20] |
Hinson, J.P.; Kapas, S.; Smith, D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr. Rev. 2000, 21, 138–167.
|
| [21] |
Lisy, O.; Jougasaki, M.; Schirger, J.A.; Chen, H.H.; Barclay, P.T.; Burnett, J.C. Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. Am. J. Physiol. 1998, 275, F410–F414.
|
| [22] |
Machado, J.; Manfredi, L.H.; Silveira, W.A.; Gonçalves, D.A.P.; Lustrino, D.; Zanon, N.M.; Kettelhut, I.C.; Navegantes, L.C. Calcitonin gene-related peptide inhibits autophagic-lysosomal proteolysis through cAMP/PKA signaling in rat skeletal muscles. Int. J. Biochem. Cell Biol. 2016, 72, 40–50.
|
| [23] |
Cruden, N.L.M.; Witherow, F.N.; Webb, D.J.; Fox, K.A.A.; Newby, D.E. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Arterioscler. Thromb. Vasc. Biol. 2004, 24, 1043–1048.
|
| [24] |
Nilsson, C.; Hansen, T.K.; Rosenquist, C.; Hartmann, B.; Kodra, J.T.; Lau, J.F.; Clausen, T.R.; Raun, K.; Sams, A. Long acting analogue of the calcitonin gene-related peptide induces positive metabolic effects and secretion of the glucagon-like peptide-1. Eur. J. Pharmacol. 2016, 773, 24–31.
|
| [25] |
Kario, K.; Sun, N.L.; Chiang, F.T.; Supasyndh, O.; Baek, S.H.; Inubushi-Molessa, A.; Zhang, Y.; Gotou, H.; Lefkowitz, M.; Zhang, J. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014, 63, 698–705.
|
| [26] |
Mitchell, G.F.; Izzo, J.L.; Lacourcière, Y.; Ouellet, J.P.; Neutel, J.; Qian, C.L.; Kerwin, L.J.; Block, A.J.; Pfeffer, M.A. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation. 2002, 105, 2955–2961.
|
| [27] |
Williams, B.; Cockcroft, J.R.; Kario, K.; Zappe, D.H.; Brunel, P.C.; Wang, Q.; Guo, W.N. Effects of sacubitril/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study. Hypertension. 2017, 69, 411–420.
|
| [28] |
Solomon, S.D.; Zile, M.; Pieske, B.; Voors, A.; Shah, A.; Kraigher-Krainer, E.; Shi, V.; Bransford, T.; Takeuchi, M.; Gong, J.J.; Lefkowitz, M.; Packer, M.; McMurray, J.J.;. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012, 380, 1387–1395.
|
| [29] |
Modin, D.; Andersen, D.M.; Biering-Sørensen, T. Echo and heart failure: when do people need an echo, and when do they need natriuretic peptides? Echo Res. Pract. 2018, 5, R65–R79.
|
| [30] |
Scott, D.; Solomon, John J.V.; McMurray, Inder S.; Anand, D.; Phil,Junbo Ge.; Carolyn S.P.L. Rouleau Angiotensin-Neprilysin Inhibition in Hear Failure with Preserved Ejection Fraction. New England J. Med. 2019, 1, 1–11.
|
)
>
>